We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+12.86%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-13.81%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Expedia Group
EXPE
|
+$752K |
| 2 |
Gartner
IT
|
+$681K |
| 3 |
Trane Technologies
TT
|
+$681K |
| 4 |
Eaton
ETN
|
+$660K |
| 5 |
Prologis
PLD
|
+$658K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$778K |
| 3 |
IDEX
IEX
|
+$731K |
| 4 |
Tesla
TSLA
|
+$719K |
| 5 |
Yum China
YUMC
|
+$714K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Summit Therapeutics
SMMT
$10.2B
| $91.5K | 0.06% |
35,069
-15,645
| -31% | -$32.2K |
|
|
MORF
402
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $90.5K | 0.06% |
3,133
+1,479
| +89% | +$35.2K |
|
|
VERV
403
DELISTED
Verve Therapeutics
VERV
| $90.1K | 0.06% |
6,465
+683
| +12% | +$8.47K |
|
404
Tango Therapeutics
TNGX
$4.21B
| $90K | 0.06% |
+9,086
| New | +$78.9K |
|
405
Viking Therapeutics
VKTX
$3.88B
| $89.6K | 0.06% |
4,817
+399
| +9% | +$5.22K |
|
406
Lyell Immunopharma
LYEL
$318M
| $88.9K | 0.06% |
2,292
+859
| +60% | +$30.9K |
|
407
Intellia Therapeutics
NTLA
$1.51B
| $88.6K | 0.06% |
2,906
+714
| +33% | +$20.5K |
|
408
Geron
GERN
$898M
| $88.4K | 0.06% |
41,892
+9,887
| +31% | +$19.2K |
|
409
TG Therapeutics
TGTX
$8.19B
| $87.8K | 0.06% |
5,143
+1,509
| +42% | +$17.5K |
|
410
Editas Medicine
EDIT
$399M
| $86.5K | 0.05% |
8,541
-373
| -4% | -$3.27K |
|
|
NUVL
411
DELISTED
Nuvalent
NUVL
| $86.2K | 0.05% |
1,172
-1,124
| -49% | -$69.6K |
|
412
Prothena Corp
PRTA
$448M
| $86.2K | 0.05% |
2,373
+1,001
| +73% | +$38.5K |
|
413
Caribou Biosciences
CRBU
$146M
| $86K | 0.05% |
15,005
-6,353
| -30% | -$31.4K |
|
414
Denali Therapeutics
DNLI
$3.79B
| $85.7K | 0.05% |
3,994
+949
| +31% | +$18.8K |
|
415
Beam Therapeutics
BEAM
$2.68B
| $84.6K | 0.05% |
+3,108
| New | +$77.2K |
|
|
ALLK
416
DELISTED
Allakos
ALLK
| $80.2K | 0.05% |
29,391
+9,214
| +46% | +$20.8K |
|
417
Regenxbio
RGNX
$616M
| $79.8K | 0.05% |
4,447
-578
| -12% | -$10.2K |
|
418
Novavax
NVAX
$1.21B
| $78.1K | 0.05% |
16,271
+3,458
| +27% | +$21.2K |
|
419
BlackRock 2037 Municipal Target Term Trust
BMN
$157M
| $77.8K | 0.05% |
3,270
-1,209
| -27% | -$28K |
|
420
uniQure
QURE
$2.75B
| $77.4K | 0.05% |
11,430
+6,326
| +124% | +$41.8K |
|
|
FLNA
421
Filana Therapeutics
FLNA
$42M
| $69.2K | 0.04% |
3,075
-832
| -21% | -$17.6K |
|
|
CVAC
422
DELISTED
CureVac
CVAC
| $67.4K | 0.04% |
16,018
+6,295
| +65% | +$34.1K |
|
423
Structure Therapeutics
GPCR
$3.37B
| $64.4K | 0.04% |
1,580
-1,614
| -51% | -$92.5K |
|
424
Copel
ELPC
$8.47B
| $44.5K | 0.03% |
+5,657
| New | +$44.5K |
|
425
Scilex Holding
SCLX
$46.1M
| $32.4K | 0.02% |
504
| – | – |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2023 Portfolio in Review
As of Q4 2023, Virtus ETF Advisers held 474 positions worth $158M, down 4.3% from $165M the previous quarter. Its ten largest holdings account for 5.6% of the portfolio.
Virtus ETF Advisers withdrew a net $21.7M in Q4 2023, closing 49 positions and reducing 231 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $854K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in Expedia Group worth $932K.
- Virtus ETF Advisers's largest Q4 2023 buy was Expedia Group: 6,139 shares worth $932K.
- Virtus ETF Advisers added most to Pioneer Natural Resource Co. in Q4 2023, an estimated $535K increase.
- Virtus ETF Advisers's biggest Q4 2023 reduction was VICI Properties, cutting an estimated $659K.
- Virtus ETF Advisers fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $854K.
- Virtus ETF Advisers's ten largest holdings make up 5.6% of its $158M portfolio in Q4 2023.
- Virtus ETF Advisers opened 40 new positions and closed 49 in Q4 2023.
- Virtus ETF Advisers's portfolio value fell 4.3% quarter-over-quarter to $158M.
Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.